Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease

Kadoaki Oohashi, Yosef E. Maruvka, Franziska Michor, William Pao

Research output: Contribution to journalArticle

306 Citations (Scopus)

Abstract

Purpose EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here, we present an update on new controversies and conclusions regarding the disease. Methods This article reviews the clinical implications of EGFR mutations in lung cancer with a focus on epidermal growth factor receptor tyrosine kinase inhibitor resistance. Results The discovery of EGFR mutations has altered the ways in which we consider and treat non-small-cell lung cancer (NSCLC). Patients whose metastatic tumors harbor EGFR mutations are expected to live longer than 2 years, more than double the previous survival rates for lung cancer. Conclusion The information presented in this review can guide practitioners and help them inform their patients about EGFR mutations and their impact on the treatment of NSCLC. Efforts should now concentrate on making EGFR-mutant lung cancer a chronic rather than fatal disease.

Original languageEnglish
Pages (from-to)1070-1080
Number of pages11
JournalJournal of Clinical Oncology
Volume31
Issue number8
DOIs
Publication statusPublished - Mar 10 2013
Externally publishedYes

Fingerprint

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Lung Neoplasms
Mutation
Non-Small Cell Lung Carcinoma
Survival Rate
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. / Oohashi, Kadoaki; Maruvka, Yosef E.; Michor, Franziska; Pao, William.

In: Journal of Clinical Oncology, Vol. 31, No. 8, 10.03.2013, p. 1070-1080.

Research output: Contribution to journalArticle

Oohashi, Kadoaki ; Maruvka, Yosef E. ; Michor, Franziska ; Pao, William. / Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. In: Journal of Clinical Oncology. 2013 ; Vol. 31, No. 8. pp. 1070-1080.
@article{c6612e000da14561981121024805bc71,
title = "Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease",
abstract = "Purpose EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here, we present an update on new controversies and conclusions regarding the disease. Methods This article reviews the clinical implications of EGFR mutations in lung cancer with a focus on epidermal growth factor receptor tyrosine kinase inhibitor resistance. Results The discovery of EGFR mutations has altered the ways in which we consider and treat non-small-cell lung cancer (NSCLC). Patients whose metastatic tumors harbor EGFR mutations are expected to live longer than 2 years, more than double the previous survival rates for lung cancer. Conclusion The information presented in this review can guide practitioners and help them inform their patients about EGFR mutations and their impact on the treatment of NSCLC. Efforts should now concentrate on making EGFR-mutant lung cancer a chronic rather than fatal disease.",
author = "Kadoaki Oohashi and Maruvka, {Yosef E.} and Franziska Michor and William Pao",
year = "2013",
month = "3",
day = "10",
doi = "10.1200/JCO.2012.43.3912",
language = "English",
volume = "31",
pages = "1070--1080",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

TY - JOUR

T1 - Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease

AU - Oohashi, Kadoaki

AU - Maruvka, Yosef E.

AU - Michor, Franziska

AU - Pao, William

PY - 2013/3/10

Y1 - 2013/3/10

N2 - Purpose EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here, we present an update on new controversies and conclusions regarding the disease. Methods This article reviews the clinical implications of EGFR mutations in lung cancer with a focus on epidermal growth factor receptor tyrosine kinase inhibitor resistance. Results The discovery of EGFR mutations has altered the ways in which we consider and treat non-small-cell lung cancer (NSCLC). Patients whose metastatic tumors harbor EGFR mutations are expected to live longer than 2 years, more than double the previous survival rates for lung cancer. Conclusion The information presented in this review can guide practitioners and help them inform their patients about EGFR mutations and their impact on the treatment of NSCLC. Efforts should now concentrate on making EGFR-mutant lung cancer a chronic rather than fatal disease.

AB - Purpose EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here, we present an update on new controversies and conclusions regarding the disease. Methods This article reviews the clinical implications of EGFR mutations in lung cancer with a focus on epidermal growth factor receptor tyrosine kinase inhibitor resistance. Results The discovery of EGFR mutations has altered the ways in which we consider and treat non-small-cell lung cancer (NSCLC). Patients whose metastatic tumors harbor EGFR mutations are expected to live longer than 2 years, more than double the previous survival rates for lung cancer. Conclusion The information presented in this review can guide practitioners and help them inform their patients about EGFR mutations and their impact on the treatment of NSCLC. Efforts should now concentrate on making EGFR-mutant lung cancer a chronic rather than fatal disease.

UR - http://www.scopus.com/inward/record.url?scp=84875950992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875950992&partnerID=8YFLogxK

U2 - 10.1200/JCO.2012.43.3912

DO - 10.1200/JCO.2012.43.3912

M3 - Article

C2 - 23401451

AN - SCOPUS:84875950992

VL - 31

SP - 1070

EP - 1080

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -